Skip to Main Content

Naftali Kaminski, MD

Boehringer Ingelheim Pharmaceuticals, Inc. Professor of Medicine (Pulmonary); Section Chief, Pulmonary, Critical Care & Sleep Medicine

Dr. Kaminski is an internationally renowned expert in genomics of chronic lung disease, biomarkers discovery and molecular mechanisms of Pulmonary Fibrosis, as well as a role model and an established mentor.

Among his key scientific achievements are: The discovery of novel molecules with significant active roles in pulmonary fibrosis, including matrix metalloproteases (MMP7, MMP19) and phosphatases (SHP2, MKP5) , demonstrating that microRNAs, a family of small non-coding RNAs, are differentially expressed in IPF, and that some of them (let-7, mir-29, mir-33) are mechanistically involved in lung fibrosis, and the discovery that the outcome of patients with IPF can be predicted based on the expression of peripheral blood proteins and genes, a finding with practical implication because of the need for risk stratification and transplant prioritization. More recently Dr. Kaminski's team identified a potential antifibrotic role for thyroid hormone signaling, a novel discovery with significant therapeutic implications, and performed single cell RNA sequencing on >300,000 cells obtained from patients with advanced lung disease and created an online freely available data dissemination tool (www.IPFCellAtlas.com). Dr. Kaminski has authored more than 275 research papers (including in Nature Medicine, NEJM, Nature Genetics, PNAS, Science Translational Medicine, Science Advances, Lancet Resp Medicine, American Journal of Respiratory and Critical Care Medicine), review articles and book chapters and has given numerous invited talks at national, international conferences, and NIH workshops. Dr. Kaminski has been consistently funded by NIH since 2003 and is currently PI of multiple NIH grants including the NIH-MHLBI funded training program "Training in Translational lung Biology and Pathobiology.

Dr. Kaminski’s awards include the Coalition for Pulmonary Fibrosis Marvin I. Schwarz Award for Pulmonary Fibrosis, the University of Pittsburgh Innovator Award, the American Thoracic Society Recognition of Scientific Achievements award, the Helmholtz Institute International Fellow Award, the European Respiratory Society Gold Medal for Interstitial Lung Disease, and the Andy Tager Excellence in Mentoring Award. Kaminski recently completed his term as Deputy Editor of Throax BMJ, and as the President of the Association of Pulmonary, Critical Care, and Sleep Medicine Division Directors where he drove gender equality, career development and wellness in pulmonary medicine initiatives.

Dr. Kaminski is passionate and committed about training physician scientists and PhD researchers for the challenges of 21st century pulmonary medicine. He has mentored 34 post-doctoral trainees, and many of them hold prominent faculty positions.



.